Ferreira Aliana Meneses, Ramos Jessica Fernandes, Fatobene Giancarlo, Rocha Vanderson
Hematology and Bone Marrow Department, Hospital Sirio Libanes, Sao Paulo, Brazil.
Infectious Diseases Department, Hospital Sirio Libanes, Sao Paulo, Brazil.
Case Rep Hematol. 2019 Mar 26;2019:8982937. doi: 10.1155/2019/8982937. eCollection 2019.
Brentuximab vedotin (BV), an antibody drug conjugate against CD30, has been increasingly used in clinical practice, and the less common adverse events associated to the drug are not well described. Also, opportunistic infections have been reported, and data on immune reconstitution after use of BV are lacking. The authors describe a case of a 45-year-old man with Hodgkin lymphoma receiving BV as a consolidation therapy after autologous hematopoietic stem cell transplant. After nine months of consolidation with BV, the patient developed a respiratory disorder characterized by fever, chills, dyspnea, and hypoxemia, and pneumonia by (PJ) was confirmed by bronchoscopy with bronchoalveolar lavage. In spite of the fact that there are no specific recommendations about infectious prophylaxis in patients using the drug, we would like to draw the attention of professionals who use the medication in relation to the risk of opportunistic infections, such as pneumonia by PJ.
本妥昔单抗（BV）是一种抗CD30的抗体药物偶联物，在临床实践中的应用越来越广泛，而与该药物相关的较少见不良事件尚无充分描述。此外，已有机会性感染的报道，但使用BV后免疫重建的数据尚缺乏。作者描述了一例45岁霍奇金淋巴瘤男性患者，在自体造血干细胞移植后接受BV作为巩固治疗。在使用BV巩固治疗九个月后，患者出现以发热、寒战、呼吸困难和低氧血症为特征的呼吸系统疾病，经支气管镜检查及支气管肺泡灌洗确诊为耶氏肺孢子菌肺炎（PJ）。尽管对于使用该药物的患者没有关于感染预防的具体建议，但我们希望引起使用该药物的专业人员对机会性感染风险的关注，如PJ所致肺炎。
